JP2022549272A - Ｅｇｆｒ阻害剤とｃｄｋ４／６阻害剤の組み合わせを用いたｅｇｆｒ変異に関連する癌の治療 - Google Patents

Ｅｇｆｒ阻害剤とｃｄｋ４／６阻害剤の組み合わせを用いたｅｇｆｒ変異に関連する癌の治療 Download PDF

Info

Publication number
JP2022549272A
JP2022549272A JP2022518263A JP2022518263A JP2022549272A JP 2022549272 A JP2022549272 A JP 2022549272A JP 2022518263 A JP2022518263 A JP 2022518263A JP 2022518263 A JP2022518263 A JP 2022518263A JP 2022549272 A JP2022549272 A JP 2022549272A
Authority
JP
Japan
Prior art keywords
formula
cancer
egfr
hydrogen
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022518263A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549272A5 (https=
Inventor
ニコラス グレコ，マイケル
ジョン コスタンゾ，マイケル
アラン グリーン，マイケル
ジャン，ドン
ペン，ジロン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beta Pharma Inc
Original Assignee
Beta Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma Inc filed Critical Beta Pharma Inc
Publication of JP2022549272A publication Critical patent/JP2022549272A/ja
Publication of JP2022549272A5 publication Critical patent/JP2022549272A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022518263A 2019-09-23 2020-09-23 Ｅｇｆｒ阻害剤とｃｄｋ４／６阻害剤の組み合わせを用いたｅｇｆｒ変異に関連する癌の治療 Pending JP2022549272A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962904567P 2019-09-23 2019-09-23
US62/904,567 2019-09-23
PCT/US2020/052096 WO2021061695A1 (en) 2019-09-23 2020-09-23 Treatment of egfr mutant-related cancers using a combination of egfr and cdk4/6 inhibitors

Publications (2)

Publication Number Publication Date
JP2022549272A true JP2022549272A (ja) 2022-11-24
JP2022549272A5 JP2022549272A5 (https=) 2023-10-02

Family

ID=75166417

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022518263A Pending JP2022549272A (ja) 2019-09-23 2020-09-23 Ｅｇｆｒ阻害剤とｃｄｋ４／６阻害剤の組み合わせを用いたｅｇｆｒ変異に関連する癌の治療

Country Status (7)

Country Link
US (1) US12390464B2 (https=)
EP (1) EP4034121A4 (https=)
JP (1) JP2022549272A (https=)
CN (1) CN114430681A (https=)
AU (1) AU2020352528A1 (https=)
TW (1) TW202126305A (https=)
WO (1) WO2021061695A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220079944A1 (en) * 2019-01-29 2022-03-17 Beta Pharma, Inc. 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017522390A (ja) * 2014-07-24 2017-08-10 ベータ ファーマ，インコーポレイテッド サイクリン依存性キナーゼ（ｃｄｋ）阻害剤としての２−ｈ−インダゾール誘導体およびその治療上の使用
JP2017533266A (ja) * 2014-11-05 2017-11-09 インベンティスバイオ シャンハイ リミテッド ピリミジン又はピリジン系化合物、それらの製造方法及び医薬使用
JP2017537114A (ja) * 2014-12-11 2017-12-14 ベータ ファーマ，インコーポレイテッド Ｅｇｆｒモジュレーターとしての置換２−アミノピリミジン誘導体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190275049A1 (en) * 2016-11-16 2019-09-12 Pfizer Inc. Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer
EP3585389A4 (en) * 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017522390A (ja) * 2014-07-24 2017-08-10 ベータ ファーマ，インコーポレイテッド サイクリン依存性キナーゼ（ｃｄｋ）阻害剤としての２−ｈ−インダゾール誘導体およびその治療上の使用
JP2017533266A (ja) * 2014-11-05 2017-11-09 インベンティスバイオ シャンハイ リミテッド ピリミジン又はピリジン系化合物、それらの製造方法及び医薬使用
JP2017537114A (ja) * 2014-12-11 2017-12-14 ベータ ファーマ，インコーポレイテッド Ｅｇｆｒモジュレーターとしての置換２−アミノピリミジン誘導体

Also Published As

Publication number Publication date
US12390464B2 (en) 2025-08-19
WO2021061695A1 (en) 2021-04-01
TW202126305A (zh) 2021-07-16
US20220347177A1 (en) 2022-11-03
AU2020352528A1 (en) 2022-04-21
EP4034121A4 (en) 2023-10-18
CN114430681A (zh) 2022-05-03
EP4034121A1 (en) 2022-08-03

Similar Documents

Publication Publication Date Title
US20240299388A1 (en) Erk1/2 and shp2 inhibitors combination therapy
JP7193475B2 (ja) ジアリール大環状化合物を含む併用療法
TW202529768A (zh) 癌症治療的療法
CN114366743A (zh) 具有驱动致癌突变的癌症的治疗
CN105828822A (zh) 用于治疗癌症的组合疗法
MX2012012051A (es) Compuesto organico para usarse en el tratamiento de cancer de higado.
TW202133856A (zh) 涉及二芳基巨環化合物之組合療法
CN104519887A (zh) 包含B-Raf抑制剂、EGFR抑制剂和任选PI3Kα抑制剂的药物组合
US9682082B2 (en) Combinations of AKT and MEK inhibitor compounds, and methods of use
JP7670711B2 (ja) ジアリール大環状化合物を含む併用療法
JP2021525244A (ja) 腫瘍性疾患を治療するための薬剤の調製におけるｅｇｆｒ阻害剤と組み合わせたｃｄｋ４／６阻害剤の使用
JP2019048822A (ja) Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用
TW202342047A (zh) 使用經取代之嘧啶-4(3h)-酮及索托拉西布(sotorasib)之組合療法
JP2021100972A (ja) がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
JP2022549272A (ja) Ｅｇｆｒ阻害剤とｃｄｋ４／６阻害剤の組み合わせを用いたｅｇｆｒ変異に関連する癌の治療
TWI623315B (zh) ３－［（３－｛［４－（４－嗎啉基甲基）－１ｈ－吡咯－２－基］亞甲基｝－２－側氧基－２，３－二氫－１ｈ－吲哚－５－基）甲基］－１，３－噻唑啶－２，４－二酮及ｅｇｆｒ ｔｙｒ激酶抑制劑之新穎結合物
CN121013721A (zh) 包含kras抑制剂和sph2抑制剂的组合疗法
HK40066730A (zh) 具有驱动致癌突变的癌症的治疗
NZ617243B2 (en) Combinations of akt and mek inhibitor compounds, and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251202